No Data
No Data
Focusing on three Nobel Prize directions, Crystal Tai Technology-P (02228), which has stepped into the forefront, will become the leader in the AI pharmaceutical blue ocean market.
The Nobel Prize, as a benchmark for the development of technology, this year's preference for AI to some extent represents the future trend of the industry. As AI technology demonstrates stronger potential and value in the global biomedical field, the intrinsic value of Crystal Technology is also expected to be further unleashed.
Express News | Ailux Biologics, a Division of Xtalpi, Enters Into a License Agreement With Janssen Biotech on Biologics AI Platform
Hong Kong stocks unusual movement | Crystal Tai Technology-P (02228) rose more than 7% in early trading, reaching a strategic cooperation with Xinxi Group, the company enters the new materials field.
Jingtai Technology - P (02228) rose more than 7% in the morning session, as of the time of writing, up 5.48%, trading at 11.18 Hong Kong dollars, with a turnover of 8.4022 million Hong Kong dollars.
XtalPi Launches Computational Chemistry Software for Drug Discovery: XMolGen and XFEP
QUANTUMPH-P: 2024 INTERIM REPORT
QUANTUMPH-P(02228) invalidates 2.045 million shares from members and returns them to the company's share capital for free.
QUANTUMPH-P (02228) announced that, according to written notice from company members, the cancellation was made by members without...
No Data
No Data